These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 10211542)

  • 1. Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme A reductase-inhibitor therapy.
    Strauss WE; Alexis G; Tapley RD
    Clin Ther; 1999 Feb; 21(2):422-9. PubMed ID: 10211542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use over time of statins in coronary patients in an Italian tertiary referral center.
    Gaspardone A; Proietti I; Altamura L; Tomai F; Versaci F; Crea F; Chiariello L; Gioffrè PA
    Ital Heart J; 2001 Nov; 2(11):848-53. PubMed ID: 11770871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of medical guidelines for the prescription of statins].
    Chevalier C; Giral P; Chinaud F; Carzon M; Gartenlaub D; Blanchon B; Trutt B
    Rev Epidemiol Sante Publique; 2002 Oct; 50(5):463-73. PubMed ID: 12471339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.
    Martin JE; Cavanaugh TM; Trumbull L; Bass M; Weber F; Aranda-Michel J; Hanaway M; Rudich S
    Clin Transplant; 2008; 22(1):113-9. PubMed ID: 18217912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperlipidemia in cardiac transplant recipients.
    Bilchick KC; Henrikson CA; Skojec D; Kasper EK; Blumenthal RS
    Am Heart J; 2004 Aug; 148(2):200-10. PubMed ID: 15308989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
    Ugawa T; Kakuta H; Moritani H; Shikama H
    Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.